BRCA1 and neoplasm: The current study evaluates BRCA-deficient HGSC by first focusing on gBRCApv-carriers and then expanding to include somatic mutations and promoter methylation in BRCA1/2, and other key HR genes, as well as evaluating tumor HRD status.